Galecto, Inc. announced topline results from its Phase 2b GALACTIC-1 trial for the treatment of idiopathic pulmonary fibrosis (IPF), which did not meet its primary endpoint, leading to the discontinuation of development of GB0139. The company will now focus on development opportunities for severe liver diseases.